Q1 Earnings Forecast for CGTX Issued By HC Wainwright

Cognition Therapeutics, Inc. (NASDAQ:CGTX) – HC Wainwright issued their Q1 2027 earnings per share (EPS) estimates for Cognition Therapeutics in a research report issued on Friday, March 27th. HC Wainwright analyst R. Selvaraju expects that the company will post earnings per share of ($0.05) for the quarter. HC Wainwright currently has a “Buy” rating and a $3.00 target price on the stock. The consensus estimate for Cognition Therapeutics’ current full-year earnings is ($0.80) per share. HC Wainwright also issued estimates for Cognition Therapeutics’ Q2 2027 earnings at ($0.05) EPS, Q3 2027 earnings at ($0.05) EPS and Q4 2027 earnings at ($0.05) EPS.

A number of other research firms have also recently commented on CGTX. Chardan Capital reiterated a “buy” rating and issued a $4.00 price objective on shares of Cognition Therapeutics in a report on Friday. Weiss Ratings restated a “sell (d-)” rating on shares of Cognition Therapeutics in a research note on Monday, December 29th. Finally, raised shares of Cognition Therapeutics to a “strong-buy” rating in a report on Tuesday, February 3rd. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $3.33.

Cognition Therapeutics Stock Performance

CGTX opened at $0.73 on Monday. The stock’s fifty day simple moving average is $1.13 and its 200 day simple moving average is $1.42. Cognition Therapeutics has a 1-year low of $0.22 and a 1-year high of $3.83. The stock has a market cap of $65.23 million, a PE ratio of -2.21 and a beta of 1.25.

Cognition Therapeutics (NASDAQ:CGTX) last issued its earnings results on Thursday, March 26th. The company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.06) by $0.04.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in CGTX. Jones Financial Companies Lllp bought a new position in Cognition Therapeutics during the 3rd quarter worth $25,000. Essex Financial Services Inc. bought a new stake in shares of Cognition Therapeutics in the fourth quarter valued at about $27,000. Gamco Investors INC. ET AL acquired a new position in shares of Cognition Therapeutics in the third quarter valued at about $27,000. Private Management Group Inc. acquired a new position in shares of Cognition Therapeutics in the third quarter valued at about $32,000. Finally, CWA Asset Management Group LLC bought a new position in Cognition Therapeutics during the third quarter worth about $34,000. Institutional investors own 43.35% of the company’s stock.

Key Headlines Impacting Cognition Therapeutics

Here are the key news stories impacting Cognition Therapeutics this week:

• Positive Sentiment: Q4 / year‑end 2025 results: CGTX reported adjusted results that beat consensus — EPS of ($0.02) vs. ($0.06) expected — signaling a smaller loss than anticipated. MarketBeat Earnings
• Positive Sentiment: Clinical development progress: Management reiterated advancement of zervimesine for DLB psychosis and expects a meeting with the FDA Division of Psychiatry by mid‑2026 — a concrete regulatory milestone that could define next‑step study requirements or timing. GlobeNewswire Release
• Positive Sentiment: Analyst support: Chardan Capital reaffirmed a “buy” rating and set a $4.00 price target, implying substantial upside versus current levels — a bullish endorsement that could attract longer‑term investors. Benzinga
• Neutral Sentiment: Additional disclosures and call materials: The company published its year‑end 2025 financial report and hosted a management call; full transcripts and summaries are available for investors who want details on pipeline timing, cash position, and management commentary. Earnings Call Transcript
• Negative Sentiment: Heavy selling pressure and volatility: the stock is down sharply on much higher volume than average (several million shares traded vs. an ~943k average), indicating large-scale selling or short‑term profit taking. That flow, combined with typical biotech risks (limited near‑term revenue, potential financing/dilution questions), likely overwhelmed the positive news and pushed the share price lower. MarketBeat Quote

About Cognition Therapeutics

Cognition Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing disease-modifying therapies for neurodegenerative disorders, with an emphasis on Alzheimer’s disease. The company’s lead investigational candidate, CT1812, is an oral small molecule that antagonizes the sigma-2 receptor complex to protect synapses from amyloid-beta oligomer toxicity. By targeting a novel mechanism of action, Cognition Therapeutics aims to slow or reverse cognitive decline in patients living with Alzheimer’s disease.

CT1812 has successfully completed Phase 1 safety studies and preliminary Phase 2a trials, and is currently being evaluated in multiple Phase 2 clinical studies across North America and Europe in patients with mild-to-moderate Alzheimer’s disease.